A Single-center, Randomized, Parallel, Open-label , Bioequivalence Study to Compare the Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Vunakizumab (Primary)
- Indications Plaque psoriasis; Spondylarthritis
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 27 Aug 2020 New trial record